Wellington Management Group LLP Has $1.13 Billion Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Wellington Management Group LLP increased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 78.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,958,543 shares of the company's stock after purchasing an additional 3,059,255 shares during the quarter. Wellington Management Group LLP owned approximately 1.55% of Zoetis worth $1,133,755,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. lifted its holdings in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares during the period. Murphy & Mullick Capital Management Corp purchased a new position in shares of Zoetis during the fourth quarter valued at $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis during the fourth quarter valued at $58,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last 90 days. 0.16% of the stock is owned by company insiders.

Remove Ads

Zoetis Stock Performance

ZTS traded down $3.76 on Thursday, hitting $159.74. The company had a trading volume of 2,243,293 shares, compared to its average volume of 2,598,407. The stock has a market cap of $71.53 billion, a price-to-earnings ratio of 29.25, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company's fifty day moving average price is $166.20 and its 200 day moving average price is $173.98. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. Zoetis's dividend payout ratio is presently 36.56%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price for the company. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.